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A METHODOLOGICAL APPROACH TO ASSESS COST DATA IN
THE CONTEXT OF A DECISION ANALYTIC MODEL TO
EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT
OF THE METABOLIC SYNDROME
Aidelsburger P1,Wasem J2
1CAREM GmbH, Egling, Germany; 2University of Duisburg-Essen,
Essen, NRW, Germany
OBJECTIVES: The metabolic syndrome is an accumulation of
risk factors and shows a high prevalence in the German popu-
lation. Treatment is limited to the treatment of single risk factors
as dyslipidemia or high blood pressure. A decision analytic
model will be developed to assess the cost-effectiveness of a new
pharmacological substance for the treatment of the metabolic
syndrome. In this context a methodological approach was devel-
oped to evaluate cost data that enables decision analyst to use
cost data for various treatment options. METHODS: Direct and
indirect costs were considered for different treatment options
and for costs of long-term complications of the metabolic syn-
drome. Field and desk research was done to obtain data con-
cerning resource utilisation and was reviewed by clinical experts.
Prices have been taken of ofﬁcial catalogues. Resource utilisation
and prices have been related in a cost database that enables to
give cost data for different treatment options and long-term com-
plications of the metabolic syndrome. RESULTS: The German
Metabolic Syndrome Cost Database includes information of
resource utilisation prices and costs. The database is constructed
in a way that it supports analysis from different perspectives.
CONCLUSIONS: A ﬂexible database was developed that
enables the adaptation of cost data for future projects due to new
developments in treatment of the metabolic syndrome.
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DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK
ASSESSMENT MODEL TO PREDICT PHARMACY
EXPENDITURES IN A U.S. MEDICAID POPULATION
Cantrell CR1, Martin BC2
1GlaxoSmithKline, RTP, NC, USA; 2University of Arkansas for Medical
Sciences, Little Rock, AR, USA
OBJECTIVES: To empirically develop and validate the Medic-
aid RxCost Model, a prospective risk assessment model, that
uses claims-based diagnostic information to predict future phar-
macy expenditures. The Medicaid Mixed RxCost (MRxCost)
Model was developed to explore the gain in predictive power
associated with adding drug information. METHODS: A retro-
spective longitudinal cohort study using a California Medicaid
sample from 1998 through 2000 was undertaken. Persons who
were continuously enrolled for at least 13 months, who were 18
to 64 years of age, not eligible for Medicare and were not admit-
ted for a hospital or nursing home stay >30 days were selected.
A training sample consisting of 138,454 persons was utilized to
develop the models using OLS regression. A random holdout
sample of 92,621 was utilized to validate the models and to
compare the performance of each model. The discrimination of
the models was also compared to a demographic model and the
Chronic Illness and Disability Payment System (CDPS) model.
Prediction ratios and measures of discrimination were estimated
for hypothetical physician groups with varying patient sizes.
RESULTS: Subjects were on average 35 years old, 72% were
female, and annualized prescription expenditures were $497.
Out of a total of 101 variables explored for the Rx-Cost model,
56 were retained after variable selection procedures and clinical
review. The R-square value for the Medicaid RxCost Model, the
Medicaid MRxCost Model and the CDPS model using the vali-
dation sample was 0.24, 0.30 and 0.04 respectively. The predic-
tion ratio = 0.90 and r-square = 0.50 were highest for large hypo-
thetical physician groups (500 patients), but acceptable measures
were observed for groups as low as 10 members. CONCLU-
SIONS: The Medicaid RxCost Model was successfully developed
and it substantially outperformed the CDPS model in terms of
R-square. The Medicaid MRxCost Model proved that supple-
menting drug information can improve discriminatory power.
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PHARMACOECONOMIC ASPECTS OF THE ADMINISTRATIVE
REFORMS IN PHARMACEUTICAL SECTORS OF REPUBLIC
HEALTH DEPARTMENTS IN MONTENEGRO
Tomic Z1, Sabo A1, Bralic R2, Glomazic Z2, Mikov M1
1Medical Faculty, Novi Sad,Vojvodina, Serbia and Montenegro;
2Republic Health Department, Podgorica, -, Serbia and Montenegro
OBJECTIVES: In 2002 in Montenegro there was no efﬁcient
system which should follow up the prescribing practice in out-
patient clinics. The total expenses for drugs were so high that
they threatened to diminish the whole system of drug supply.
METHODS: Therefore in 2003 at the whole Montenegro
Republic a system to follow up the drug prescribing in outpa-
tient practice was implemented. System consisted from the
central unit in Republic health department, and units in the all
pharmacies which give drugs on the prescriptions covered ﬁnan-
cially by Republic health department. System started on
01.01.2004. System contains bases with all drugs on market in
Montenegro, all doctors, pharmacists, drug users and enables to
follow the drugs way from each doctor through pharmay to the
patient. RESULTS: At the same time Republic health department
introduced the new list of drugs refunded by Republic health
department. The list of drugs refunded by Republic health
department, so called Positive list, covered all important drugs,
and was prepared in accordance to new pharmacotherapeutic
guidelines. ATC/DDD methodology of drugs was used. Analysis
performed one year after implementation showed that the use of
drugs signiﬁcantly (1568%) decreased when compared with
2002 year. Expenses were 1.5mil E lower that on 2002/2003.
From the all drugs, the most often issued drugs were for arter-
ial hypertension and for tonsilopharingitis, more than 25% of
all prescriptions. The structure of drugs prescribed was improved
when compared with pre implementation period. CONCLU-
SIONS: Permanent monitoring and periodic analyses of infor-
mations obtained from information system in the future will
additionally improve rationalization of the drug prescribing.
Monitoring and analyses will show if some other administrative
measurements are needed to keep this positive trend on.
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ECONOMIC IMPACT OF HOSPITAL MALNUTRITION
Ethgen O1, Spaepen E2, Moeremans K2,Annemans L2
1University of Liège, Liège, Belgium; 2IMS Health, Brussels, Belgium
OBJECTIVE: Malnutrition during hospital stay has been con-
sistently reported since the 1970s. In addition to the clinical
implications malnutrition may have, it also leads to increased
length of stay and drug usage due to complications. We report
from a large observational database of 26 Belgian hospitals to
document the potential economic impact of hospital malnutri-
tion. METHODS: As a legal requirement, Belgian hospitals must
register case-mix data for each inpatient stay in a minimum basic
data set (MBDS). We extracted exhaustive and anonymous stay
data from 26 hospitals (2nd semester, 2003) and identiﬁed mal-
nourished patients as patients for whom ICD9-CM codes for
“underweight” (783.22) or “severe weight loss” (783.21) were
recorded. A matched analysis on APR-DRG, age and gender was
then performed to compare inpatient pharmaceuticals costs, pro-
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cedures costs, hotel cost and overall costs between malnourished
and normally nourished patients. RESULTS: A total of 1032
malnourished patients were identiﬁed. Of those, “underweight”
or “severe weight loss” was the primary diagnosis for 105
patients and the secondary diagnosis for 927 patients. Therefore,
only these 927 patients were included in the matched analysis.
In all, 26,067 matched controls were retrieved. The overall mean
cost difference per stay between malnourished and normally
nourished patients averaged €1152 (95%CI: €870; €1433). Phar-
maceuticals, procedures and hotel costs differences averaged
€264 (€192; €336), €137 (€113; €161) and €754 (€508; €1000),
respectively. The largest mean cost difference was found for
APR-DRG 691-Lymphoma & non-acute leukemia: €5117
(€2544: €7691). CONCLUSION: The inpatient cost incurred by
malnutrition is substantial and calls for routine pre- or in-
hospital nutritional screening and adequate and timely initiation
of nutritional support. However, we can not exclude the possi-
bility that only severe malnutrition was reported and recognized
through hospital registries. Further studies able to report from
the larger spectrum of malnutrition are strongly advocated.
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POPULATION KNOWLEDGE: AN APPROACH TO CLASSIFY A
GENERAL POPULATION ACCORDING TO LIFESTYLE, HEALTH
BEHAVIOUR AND ATTITUDE
Auray JP1, Nicoloyannis N2, Dinet J3
1Université Claude Bernard Lyon 1,Villeurbanne, France; 2Université
Lumière Lyon 2, Bron, France; 3Sanoﬁ-Aventis France, Paris, France
OBJECTIVES: For decision makers, epidemiological data are
key information to set up a public health care policy. By deﬁni-
tion, these quantitative data are rarely crossed with qualitative
information about population trends concerning lifestyle and
health behaviour. We developed a methodological approach to
detect and classify groups of subjects over 26 qualitative vari-
ables. METHODS: A sample of 924 French subjects was
included in a cross-sectional survey and answered a face to face
questionnaire focusing mainly on their health perception and
lifestyle. A multiple correspondence factorial analysis (MFCA)
followed by Khi 2 test validations were performed to detect and
to classify groups of subjects. RESULTS: Four subject groups (n1
= 297, n2 = 235, n3 = 241, n4 = 151) were clearly disclosed.
Group n2 was removed from the other groups and was charac-
terized by the poorest health perception, the highest number of
declared diseases (more than 6), the highest number of visits to
a physician (more than 5 per year), the lowest educational level,
the highest compliance to prescriptions and the highest number
of obese subjects. From the n2 group, we estimated the propor-
tion of obese subjects (BMI above 30kg/m2) to be 63%. For this
group, medical management and follow-up of their weight prob-
lems would be the most beneﬁcial. CONCLUSIONS: This qual-
itative analysis is an element of population knowledge which
allows us to specify usual epidemiological data. In addition, this
approach is a way to target the population who would accept
the public health message most easily.
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DIRECT AND INDIRECT COSTS AND EFFECTS IN COST-
EFFECTIVENESS ANALYSIS OF PREVENTION: A DYNAMIC
MODELLING ANALYSIS
Van Baal P, Feenstra TL, Hoogenveen R, de Wit G
National Institute of Public Health and the Environment, Bilthoven,
The Netherlands
The inclusion of indirect medical costs is a topic of ongoing dis-
cussion in the literature. Actual practice seems to be to include
only medical costs of so-called related diseases. However, this
criterion is not unambiguous since health gains in life years
gained may also depend on unrelated medical care. OBJECTIVE:
To compare different ways to include both direct and indirect
medical costs and health affects in cost effectiveness ratios.
METHODS: Smoking cessation interventions were evaluated
using a dynamic population model, the RIVM chronic disease
model. This is a multistate transition model that links prevalence
of risk factors to the incidence of 28 chronic diseases. Three dif-
ferent cost-effectiveness ratios were compared: 1) all health
effects were ascribed to the smoking cessation interventions
while only costs of smoking related diseases were taken into
account; 2) only the minimum gain in QALY’s and life years that
can be attributed to the interventions were included while only
costs of smoking related diseases were taken into account; and
3) all health effects and all health care costs in life years were
included. RESULTS: Ratio 1) equals €2650 per QALY gained.
Exclusion of health effects on competing diseases increases the
ratio to €3600 (ratio 2). Finally, if all costs and effects are
included, ratio 3) equals €8560 per QALY gained, which demon-
strates that the cost-effectiveness ratio increases enormously
when health care costs of competing diseases are taken into
account. CONCLUSION: The large differences in outcomes
urges one to think about the interpretation of cost-effectiveness
ratio’s and what ratio to use. We argue that for the evaluation
of preventive interventions in a population model, the third ratio
is the best, since it seems impossible to isolate the precise effects
of an intervention.
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THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM
(NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH
REGISTRY
Crosby A, Lipskiy N, Steenkamp M, Barker L
CDC, Atlanta, GA, USA
OBJECTIVE: The National Violent Death Reporting System
(NVDRS) is a registry of violent deaths in the United States. The
NVDRS aggregates data from multiple sources, including death
certiﬁcates, medical examiner and coroner reports, and crime
laboratories. The NVDRS currently obtains data from 17 states,
but is designed to eventually be a national registry. This study
evaluates how NVDRS can serve as a model for other develop-
ing national public health (PH) registries. METHODS: A team
of PH professionals compared the NVDRS to other national 
registries (immunization registry, cancer registries, National
Ambulatory Care Survey, National Hospital Discharge Survey
etc.) in terms of data elements’ design, efﬁciency of a hierarchi-
cal structure and data integrity, data security, etc. Comparative
analysis has been conducted using a tool that aggregates ques-
tions on qualitative registries’ metrics. RESULTS: Compared to
other registries, NVDRS has a well-deﬁned goal, sufﬁcient for
the development of a PH registry (to assist the design of PH inter-
ventions for a reduction of mortality due to violent deaths).
NVDRS is a population based, conﬁdential, incident-driven,
computerized information system. NVDRS represents a new gen-
eration of systems with the highest level of data complexity
because of the aggregation of multiple data sources obtained
from different state agencies. NVDRS encompasses essential reg-
istry functions and attributes sufﬁcient to accomplish the
system’s major goals. It has well deﬁned core elements, which
allows for many types of analysis. CONCLUSIONS: A compar-
ative analysis of NVDRS demonstrates that goals, design and
structure of this system promote best practices for the PH patient
registries.
